When considering the identified drugs that are actively utilised in cardiovascular disease treatment, amrinone is indicated for treatment of congestive heart failure, via inhibition of PDE4, PDE3A/B, and TNF signalling, thereby increasing cAMP/cGMP and calcium influx resulting in increased ionotropic activity [101]. The gene discussed is PDE4A; the disease is congestive heart failure.